Huons Global Co., Ltd. (084110.KQ)
KRW 52100.0
(3.99%)
KRW 52100.0
(3.99%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 758.37 Billion KRW | 14.15% |
| 2022 | 664.36 Billion KRW | 15.61% |
| 2021 | 574.64 Billion KRW | 9.87% |
| 2020 | 523.04 Billion KRW | 16.38% |
| 2019 | 449.42 Billion KRW | 18.68% |
| 2018 | 378.68 Billion KRW | 16.89% |
| 2017 | 323.96 Billion KRW | 97.88% |
| 2016 | 163.71 Billion KRW | 150.14% |
| 2015 | 65.44 Billion KRW | -64.11% |
| 2014 | 182.34 Billion KRW | 15.27% |
| 2013 | 158.18 Billion KRW | 17.98% |
| 2012 | 134.07 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 209.65 Billion KRW | 3.85% |
| 2024 Q1 | 201.88 Billion KRW | 0.91% |
| 2023 FY | 758.37 Billion KRW | 14.15% |
| 2023 Q1 | 173.96 Billion KRW | 6.0% |
| 2023 Q4 | 200.05 Billion KRW | 4.95% |
| 2023 Q2 | 193.74 Billion KRW | 11.37% |
| 2023 Q3 | 190.61 Billion KRW | -1.61% |
| 2022 Q4 | 164.11 Billion KRW | -3.98% |
| 2022 Q1 | 159.67 Billion KRW | 0.33% |
| 2022 FY | 664.36 Billion KRW | 15.61% |
| 2022 Q2 | 169.65 Billion KRW | 6.25% |
| 2022 Q3 | 170.92 Billion KRW | 0.75% |
| 2021 Q1 | 131.64 Billion KRW | -7.97% |
| 2021 Q2 | 143.71 Billion KRW | 9.17% |
| 2021 Q3 | 145.42 Billion KRW | 1.19% |
| 2021 Q4 | 159.15 Billion KRW | 9.44% |
| 2021 FY | 574.64 Billion KRW | 9.87% |
| 2020 Q2 | 126.19 Billion KRW | 8.21% |
| 2020 Q3 | 137.18 Billion KRW | 8.71% |
| 2020 Q4 | 143.04 Billion KRW | 4.27% |
| 2020 Q1 | 116.62 Billion KRW | -5.65% |
| 2020 FY | 523.04 Billion KRW | 16.38% |
| 2019 Q4 | 123.6 Billion KRW | 6.38% |
| 2019 Q3 | 116.19 Billion KRW | 8.21% |
| 2019 Q2 | 107.37 Billion KRW | 5.02% |
| 2019 Q1 | 102.24 Billion KRW | 0.43% |
| 2019 FY | 449.42 Billion KRW | 18.68% |
| 2018 FY | 378.68 Billion KRW | 16.89% |
| 2018 Q4 | 101.8 Billion KRW | 2.22% |
| 2018 Q3 | 99.59 Billion KRW | 8.12% |
| 2018 Q2 | 92.11 Billion KRW | 8.16% |
| 2018 Q1 | 85.16 Billion KRW | 3.04% |
| 2017 Q4 | 82.65 Billion KRW | -3.73% |
| 2017 Q1 | 73.44 Billion KRW | 0.04% |
| 2017 Q2 | 82.01 Billion KRW | 11.67% |
| 2017 Q3 | 85.85 Billion KRW | 4.68% |
| 2017 FY | 323.96 Billion KRW | 97.88% |
| 2016 Q2 | 21.77 Billion KRW | 46.35% |
| 2016 Q4 | 73.41 Billion KRW | 36.85% |
| 2016 Q3 | 53.64 Billion KRW | 146.36% |
| 2016 Q1 | 14.87 Billion KRW | -13.72% |
| 2016 FY | 163.71 Billion KRW | 150.14% |
| 2015 Q2 | 17.11 Billion KRW | 37.4% |
| 2015 Q4 | 17.24 Billion KRW | -7.44% |
| 2015 Q3 | 18.63 Billion KRW | 8.84% |
| 2015 FY | 65.44 Billion KRW | -64.11% |
| 2015 Q1 | 12.45 Billion KRW | -75.3% |
| 2014 Q3 | 46.35 Billion KRW | 4.98% |
| 2014 Q1 | 41.4 Billion KRW | -4.45% |
| 2014 Q2 | 44.15 Billion KRW | 6.63% |
| 2014 Q4 | 50.42 Billion KRW | 8.79% |
| 2014 FY | 182.34 Billion KRW | 15.27% |
| 2013 Q2 | 38.39 Billion KRW | 12.73% |
| 2013 FY | 158.18 Billion KRW | 17.98% |
| 2013 Q1 | 34.05 Billion KRW | 1.59% |
| 2013 Q3 | 42.39 Billion KRW | 10.44% |
| 2013 Q4 | 43.33 Billion KRW | 2.21% |
| 2012 FY | 134.07 Billion KRW | 0.0% |
| 2012 Q4 | 33.52 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 135.95 Billion KRW | -457.826% |
| CMG Pharmaceutical Co., Ltd. | 93.9 Billion KRW | -707.589% |
| Celltrion Pharm, Inc. | 388.79 Billion KRW | -95.059% |
| DongKook Pharmaceutical Co., Ltd. | 730.99 Billion KRW | -3.746% |
| Enzychem Lifesciences Corporation | 76.03 Billion KRW | -897.358% |
| Humedix Co., Ltd. | 152.27 Billion KRW | -398.037% |
| Boditech Med Inc. | 134.21 Billion KRW | -465.031% |
| EuBiologics Co., Ltd. | 69.36 Billion KRW | -993.307% |
| FutureChem Co.,Ltd | 13.96 Billion KRW | -5329.401% |
| Huons Co., Ltd. | 552 Billion KRW | -37.386% |
| BNC Korea Co., Ltd. | 80.99 Billion KRW | -836.3% |
| AptaBio Therapeutics Inc. | 323.86 Million KRW | -234062.605% |